ACHF.F Stock Overview
Arch Biopartners Inc., together with its subsidiaries, engages in the development of therapeutic drugs for inflammation and acute organ injuries in Canada.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Arch Biopartners Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.70 |
| 52 Week High | US$1.88 |
| 52 Week Low | US$0.72 |
| Beta | 1.34 |
| 1 Month Change | -5.90% |
| 3 Month Change | 50.00% |
| 1 Year Change | 10.78% |
| 3 Year Change | 66.18% |
| 5 Year Change | 69.50% |
| Change since IPO | 138.73% |
Recent News & Updates
Recent updates
Shareholder Returns
| ACHF.F | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | -1.5% | -4.1% | -3.2% |
| 1Y | 10.8% | -6.7% | 19.3% |
Return vs Industry: ACHF.F exceeded the US Life Sciences industry which returned -6.7% over the past year.
Return vs Market: ACHF.F underperformed the US Market which returned 19.3% over the past year.
Price Volatility
| ACHF.F volatility | |
|---|---|
| ACHF.F Average Weekly Movement | 7.5% |
| Life Sciences Industry Average Movement | 7.0% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: ACHF.F's share price has been volatile over the past 3 months.
Volatility Over Time: ACHF.F's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | Richard Muruve | www.archbiopartners.com |
Arch Biopartners Inc., together with its subsidiaries, engages in the development of therapeutic drugs for inflammation and acute organ injuries in Canada. It focuses on developing its lead drug candidate LSALT Peptide, a product in Phase 2 clinical trials to treat dipeptidase-1 mediated organ inflammation in the lungs, liver, and kidneys. The company also develops AB569 for treating antibiotic-resistant bacterial infections, and for the treatment of wounds; and Borg, a peptide-solid surface interface to reduce corrosion of metals.
Arch Biopartners Inc. Fundamentals Summary
| ACHF.F fundamental statistics | |
|---|---|
| Market cap | US$106.54m |
| Earnings (TTM) | -US$1.42m |
| Revenue (TTM) | US$1.35m |
79.0x
P/S Ratio-74.8x
P/E RatioIs ACHF.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ACHF.F income statement (TTM) | |
|---|---|
| Revenue | CA$1.85m |
| Cost of Revenue | CA$1.81m |
| Gross Profit | CA$32.20k |
| Other Expenses | CA$1.98m |
| Earnings | -CA$1.95m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.031 |
| Gross Margin | 1.74% |
| Net Profit Margin | -105.69% |
| Debt/Equity Ratio | -88.2% |
How did ACHF.F perform over the long term?
See historical performance and comparison